We performed a pilot trial in refractory cancer patients to investigate the feasibility of intratumoral injection of TAPET-CD, an attenuated Salmonella bacterium expressing the E. coli cytosine deaminase gene. A total of three patients received three dose levels of TAPET-CD (3 Â 10 6 -3 Â 10 7 CFU/m 2 ) via intratumoral injection once every 28 days as long as progression of disease or intolerable toxicity was not observed. From days 4 to 14 of each 28 day cycle, patients also received 5-fluorocytosine (5-FC) at a dose of 100 mg/kg/day p.o. divided three times daily. Six cycles of treatment were administered. No significant adverse events clearly attributable to TAPET-CD were demonstrated. Two patients had intratumor evidence of bacterial colonization with TAPET-CD, which persisted for at least 15 days after initial injection. Conversion of 5-FC to 5-fluorouracil (5-FU) as a result of cytosine deaminase expression was demonstrated in these two patients. The tumor to plasma ratio of 5-FU for these two colonized patients was 3.0, demonstrating significantly increased levels of 5-FU at the site of TAPET-CD colonization and insignificant systemic spread of the bacteria. In contrast, the tumor to plasma ratio of 5-FU of the patient who did not show colonization of TAPET-CD was less than 1.0. These results support the principle that a Salmonella bacterium can be utilized as a delivery vehicle of the cytosine deaminase gene to malignant tissue and that the delivered gene is functional (i.e. able to convert 5-FC to 5-FU) at doses at or below 3 Â 10 7 CFU/m 2 .
S
everal preclinical studies have shown that systemically administered bacteria will accumulate preferentially in the extracellular compartment of tumors. Conditions present in tumors such as hypoxia, presence of cellular debris from necrosis, high interstitial pressure that impede entry of antibodies, or the expression of immunosuppressive substances probably favor the selective growth of bacteria in the tumor microenvironment. Preclinical studies involving systemic administration of various attenuated and nonattenuated bacteria also indicate that bacterial colonization of malignant tissue can be associated with tumor necrosis and growth inhibition. [1] [2] [3] [4] In the medical literature, spontaneous infection of human tumors has been reported. [5] [6] [7] [8] [9] [10] [11] [12] [13] Based on these findings, a small number of advanced cancer patients were treated systemically (or by direct tumor injection) with non-toxinproducing strains of Clostridia in the 1960s, but this approach was abandoned due to excessive toxicity and minimal antitumor effect.
Spontaneous infection of human tumors with Salmonella species has been well-documented, [9] [10] [11] [12] [13] and for potential systemic administration as a cancer therapeutic, Salmonella offer several advantages over other bacterial species, including the relative ease of attenuation, sensitivity to antibiotics, and ability to grow in both hypoxic and well-oxygenated environments. Recently, a S. typhimurium species was genetically attenuated by deleting both the purI and msbB genes (VNP20009). administered intravenously to several species with minimal to modest reversible toxicity. 14, 15 Despite its substantial attenuation, VNP20009 effectively colonized syngeneic, spontaneous, and human tumors in mice, formed high tumor-to-normal tissue ratios (range from 250 : 1 to 25,000 : 1 compared to liver), and inhibited tumor growth. 14, 15, [19] [20] [21] Recently, a phase I clinical trial involving 25 patients, who received intravenous infusion of VNP20009, defined a maximum tolerated dose of 3 Â 10 8 CFU/m 2 . 22 Colonization of tumor was detected in three patients however, objective tumor regression was not observed. Doserelated increases in circulation of interleukin 1 beta, tumor necrosis factor alpha, and interleukin 6 appeared to be associated with clinical toxicity, that is, hypotension, fever, thrombocytopenia, anemia, diarrhea, nausea, and vomiting. 22, 23 A second study involved direct intratumoral administration of VNP20009. Approximately 2 weeks following the administration of VNP20009, VNP20009 could be detected in biopsies of most injected lesions, and in some necrosis, inflammation, and/or regression was observed. The intratumoral administration was associated with minimal to modest systemic and local toxicity at doses between 3 Â 10 6 and 3 Â 10 8 /m 2 (unpublished data). In an effort to increase the therapeutic effectiveness of VNP20009 the cytosine deaminase (CD) gene from E. coli was genetically inserted into the chromosome of VNP20009 at the DmsbB locus to create the strain TAPET-CD. 19, 20, 24 CD is an enzyme found in both bacteria and fungi, but not in mammalian cells. It converts 5-fluorocytosine (5-FC), an antifungal agent with limited systemic toxicity, to 5-fluorouracil (5-FU). 25 5-FU is a cytotoxic antimetabolite commonly used to treat colorectal, gastric, head and neck, pancreatic, and breast cancers. 26 Clinical data suggest that the antitumor activity of 5-FU is directly related to both the duration of drug exposure and its concentration in the tumor. Administration of TAPET-CD and 5-FC in murine tumor models produced selective high 5-FU concentrations in malignant tissue, which correlated with tumor colonization by TAPET-CD. 24 Intratumor concentration of 5-FU following intravenous infusion at optimal doses (60 mg/kg), associated with anticancer activity, failed to achieve similar intratumoral concentration of 5-FU compared to intravenous TAPET-CD/5-FC.
24,27 TA-PET-CD and 5-FC also demonstrated significantly enhanced antitumor activity without additional toxicity in animal models in comparison to TAPET-CD alone. 19, 20 Others have also confirmed significant improvement in antitumor activity of the encoded CD gene compared to the respective parent wild-type bacteria with different attenuated bacterial species. 28 Based on clinical data generated with the parent VNP20009 at doses up to 3 Â 10 8 CFU/m 2 and efficacy demonstrated in mice with TAPET-CD/5-FC, we initiated a pilot trial of intratumoral injection of TAPET-CD followed by oral 5-FC in patients with refractory cancer. The objectives of this trial were to determine the MTD of TAPET-CD in combination with 5-FC; to quantitate TAPET-CD colonization in tumor tissue; to determine the blood pharmacokinetics of TAPET-CD following intratumoral injection; and to determine the blood and intratumoral concentrations of 5-FC and 5-FU. Although the trial was discontinued for nonmedical issues after three patients were accrued, proof of concept was demonstrated by the intratumor conversion of 5-FC to 5-FU. No significant toxicity was observed.
Methods

Study population
Patients were eligible for this study if they had advanced and/or metastatic, histologically documented solid tumors that were considered sensitive to 5-FU and if their disease was no longer responding to available conventional modalities or treatment (failed any known standard curative or effective therapy for that disease). The specific tumor to be injected with TAPET-CD had to be at least 1.5 cm in diameter, cutaneous or subcutaneous, if in lymph nodes easily accessible near the body surface, or on a mucosal surface or in soft tissues of the extremities. All lesions had to be accessible to surgical incision and drainage. Other eligibility criteria included ECOG performance status of 0 or 1, age Z18 years, life expectancy of Z3 months, granulocyte count Z2,000/mm 3 , platelets Z100,000/mm 3 , serum creatinine r2.0 mg/dl, bilirubin, and alkaline phosphatases r1.5 Â the upper limit of normal, ALT and AST r1.5 Â the upper limit of normal, hematocrit Z30%, maximum daily temperature of r38.01C, and consent for study participation on an IRB-approved informed consent form. Women and men of reproductive potential were required to use a reliable form of contraception.
Patients were excluded from the study if their lesions were in a location that was unable to accommodate swelling or inflammation, in the central nervous system, or in the retroperitoneum or mediastinum. Other exclusion criteria included patients with metastatic lesions that would not be treated as part of the protocol and that would require palliation with surgery or other modalities in o28 days, an artificial implant that could not be easily removed, known cardiac valvular disease or arterial aneurysms, known clinically significant atherosclerotic disease, gallstones or urinary tract stones, an active infection of any kind, any known hypocoagulation disorder, documented immunodeficiency, evidence of chronic active Hepatitis B, active brain metastases, or hypersensitivity to quinoline or cephalosporin antibiotics. Patients who were currently using antibiotics, or who required chronic steroid or immunosuppressive medications were also ineligible for the study. Commercial food handlers, day-care workers, health-care workers or those unable to avoid close personal contact with severely immunosuppressed individuals were not allowed to participate in the study. This study was approved by the local institutional review board and all patient participants were required to sign consent before participation.
Design
This was an open-label, phase 1, dose-escalation study. On day 1, prior to treatment with TAPET-CD, patients were administered 500 cm 3 of D5W with half-normal saline over 2-3 hours to ensure that they were well hydrated. At 2 hours before receiving TAPET-CD they started a regimen of 650 mg of acetaminophen orally every 4 hours and 50 mg of indomethacin every 8 hours for 24 hours and then as needed for temperatures Z391C. . If all toxicities of TAPET-CD were resolved to rgrade 1 (with the exception of transaminases and hematologic abnormalities, which had to be rgrade 2), then on day 4, oral 5-FC (100 mg/kg/day divided thrice daily) was begun and continued for 14 days. This cycle was repeated on days 29 and 58 in eligible patients. Patients were monitored by CT scan after every cycle and were eligible to begin the next cycle if the injected lesion showed no signs of progression and they continued to meet all other eligibility criteria.
Monitoring of patients
Chest X-ray, physical examination, complete history, performance status, tumor staging, ultrasound of the abdomen, blood cultures, urine and stool cultures, vital signs, urinalysis, CBC and platelets, PT/PTT, liver function tests (LFTs), serum chemistry, pregnancy test, HIV test, Hepatitis B surface antigen test, EKG, and antibody response were all performed prior to treatment with TAPET-CD.
During, and following, the dose of TAPET-CD, vital signs and pulse oxygen saturation were obtained every 15 minutes for 90 minutes, then every 30 minutes x 4, then every 2 hours x 4, then every 4 hours through the first 24 hours or until discharge from the outpatient area (at least 8 hours after treatment). On days 2 and 4 patients were monitored with vital signs, performance status, CBC with platelets, serum chemistries, LFTs, urinalysis, blood cultures, and urine and stool cultures. Blood samples to perform PK analysis of TAPET-CD were drawn on day 1 and for 5-FC and 5-FU on day 4. Patients returned to the outpatient clinic on days 8 and 15 and the same procedures were performed as on day 4, with the exception that no urine and stool cultures were taken. Tumor samples, to verify TAPET-CD colonization and to measure intratumoral 5-FC and 5-FU concentrations were obtained on day 8 and, in selected patients, between days 15 and 17 to confirm the persistence of high levels of bacteria in the tumor and to provide a second measurement of 5-FC and 5-FU intratumoral concentrations. On day 11, CBC and platelets were drawn. On day 18, CBC and platelets were also drawn and a blood for PK evaluation for 5-FC and 5-FU was performed.
The NCI Common Toxicity Criteria were used to grade toxicity. The dose-limiting toxicities for TAPET-CD were defined as follows: Zgrade 3 toxicity, hypotension requiring any vasopressor support, Zgrade 2 allergic toxicity, grade 2 fever for more than 6 hours per day that persisted for 41 week and grade 2 constitutional symptoms which persisted greater than 1 week or were poorly controlled with supportive medication. Any inflammation induced in the brain, anterior chamber of the eye, or joints or grade 2 toxicities involving the central nervous system, cardiac, pulmonary, and renal function not resolving within 48 hours were also considered doselimiting toxicities.
TAPET-CD
The CD gene was cloned from E. coli by PCR using primers based on the complete sequence for the E. coli cytosine deaminase 27 : forward: 5 0 -GAT CAT GCA TGT GGA GGC TAA CAG T-3 0 and reverse 5 0 -CTA GAT GCA TCA GAC AGC CGC TGC GAA GGC-3 0 . The CD gene was further subcloned into the vector pTrc99a (Pharmacia -Upjohn) and sequenced to verify. A vector capable of undergoing homologous recombination with the DmsbB gene in the chromosome of strain VNP20009 16 was created in the suicide vector pCVD442 29 to create pCVD442-msbB. A DNA fragment from the pTrc99a-CD vector above was generated by partial digestion with SspI and subcloned into the vector pCVD442-msbB to create pCVD442-CD. The CD gene was than transduced and integrated into the chromosome of VNP20009 by the method of Donnenberg and Kaper, 29 to create the strain TAPET-CD. A Research Cell Bank (RCB) and Master Cell Bank (MCB) were created and the location and sequence of the inserted CD gene at the DmsbB locus was confirmed in the MCB by sequence analysis. The clinical lot of TAPET-CD material was produced under GMP conditions by Cambrex Bioscience (formerly Marathon Pharmaceuticals, Hopkinton, MA).
Quantitation of TAPET-CD accumulation and 5-FC/5-FU conversion in tissues
Tumor tissue was excised under sterile conditions and homogenized in PBS. Bacteria were quantitated by plating serial dilutions of the homogenates onto rich media, incubating overnight at 371C, and counting bacterial colonies. A single colony arising from a single plated bacteria which was visibly detected in the culture media was considered a positive colony. The conversion of 5-FC to 5-FU in tissue was determined by highperformance liquid chromatography (HPLC) analysis based on the maximum absorbance of 5-FU at 266 nm and 5-FC at 280 nm (Phenomenex Prodigy ODS (3) column). The detection limits for 5-FC and 5-FU were 0.5 and 0.2 mg/g respectively.
Preparation and administration of TAPET-CD
TAPET-CD was stored at À801C in 15% glycerol. Each vial contained 1.2 ml of TAPET-CD bacteria at approximately 3 Â 10 9 CFU/ml. Vials of TAPET-CD were thawed at room temperature for 15-20 minutes. The stock TAPET-CD was serially diluted into sterile normal preservative free saline and the appropriate volume of diluted TAPET-CD was divided equally between two and four injections and delivered using a 23-27 gauge needle. Prior to injection, negative pressure was created to avoid injection into the circulation. Each syringe was used to make a separate skin puncture, at approximately 60-80% of the distance from the tumor center out to the tumor periphery. The skin punctures were evenly distributed around the perimeter of the tumor and over its surface. With each skin puncture, six to eight needle tracks were made emanating out radially from the puncture site and the bacteria was distributed uniformly along the needle track by gradually depressing the syringe plunger during withdrawals of the needle. Most of the bacterial dose was delivered to the tumor periphery at the interface of the tumor and normal tissue.
Results
Patient population
Three patients received injections of TAPET-CD from 1/29/02 to 5/16/02 in the Mary Crowley Medical Research Center, Dallas, Texas. A fourth patient signed consent but withdrew during screening and did not receive treatment. Results are reported on the three patients who received treatment. Demographics of these three patients are listed in Table 1 . Dosing of TAPET-CD is listed in Table 2 .
Adverse events
Toxicity felt to be related to TAPET-CD is listed in Table 3 . One grade 3 toxicity was observed in patient 001, 4 days after initiation of cycle 3. She developed symptoms consistent with either esophageal spasm or coronary vessel spasm. Transient S-T segment EKG changes in association with chest pain were observed during a followup clinic visit. Pain and EKG changes were relieved with sublingual nitroglycerin and the patient was admitted for observation and further work-up. Cardiac enzymes were not elevated, and no evidence of obstruction by coronary catheterization was observed, no arrhythmias were observed during cardiac monitoring. The patient was released without further treatment and no recurrent events have occurred following release. Other AEs, defined in Table 3 , were likely related to reactivity to colonization of bacteria (i.e. fever and fatigue).
TAPET-CD tissue colonization and blood levels
Tissue colonization for each patient is shown in Table 4 . Patients 001 and 003 demonstrated colonization of TAPET-CD within tumor tissue. Colonization was seen in both course 1 and course 2 in patient 001. In both patients, tissue colonization persisted in tumor tissue for at least 15 days. The tumor tissue from patient 001 was contaminated with oral flora (note that this was a tumor of the oral cavity), requiring TAPET-CD to be isolated using selective media. The use of selective media is known to reduce the recovery of TAPET-CD organisms; Salmonella expressing the E. coli CD gene J Nemunaitis et al however, even under these conditions significant levels of TAPET-CD could be isolated from the tumor tissue of patient 001. The concentration of TAPET-CD in the blood was also monitored after injection. At early time points (30 minutes to 1 hour postinjection) the blood levels were detectable but below the level of accurate quantitation (mean values ranged from 1.8 to 3.0 CFU/ml). All later time points TAPET-CD values were below detection levels. The pattern of distribution of TAPET-CD throughout the tumor tissue was not assessed.
5-FC and 5-FU tissue and plasma levels
Plasma levels of 5-FC and 5-FU are provided in Table 5 . Steady-state concentration (Css) in plasma of 5-FC was achieved by day 8 and ranged from 923 to 1231 mM. The level of 5-FU in plasma also reached steady-state condition by day 8, and ranged from 0.39 to 0.62 mM.
A summary of tissue levels of 5-FC and 5-FU are shown in Table 6 for each patient. The concentration of 5-FU in tumor tissue from patients 001 and 003 was more than 5 times greater than the concentration of 5-FU in the tumor of patient 002, who did not show evidence of tumor colonization ( Table 4) . The tumor to plasma ratio for 5-FC of each patient was approximately 0.6, as would be expected for small molecule drugs ( Table 7) . The tumor to plasma ratio of 5-FU for patients 001 and 003, both of Patient 001 tissues samples from mouth, highly contaminated with multiple flora. TAPET-CD identified by selective media causing significant reduction in recovery. Salmonella expressing the E. coli CD gene J Nemunaitis et al whom had high levels of tumor colonization (Table 4) , was approximately 3.0. The tumor to plasma ratio of 5-FU for patient 002 who did not show colonization of TAPET-CD bacterium was not different from that observed with 5-FC. Tumor to plasma ratios are compared graphically in Figure 1 .
Response
Patient 001 was removed from trial during cycle 3 with stable disease due to the grade 3 toxic event previously described. Necrosis of the patient's fungating oral cavity mass was observed during the first week following each injection; however, despite external evidence of regression and improved subjective air movement with the patient's oral cavity, radiologic assessment of the overall tumor mass did not identify objective tumor regression. , and doses of at least this magnitude were administered in the intratumoral study. Higher levels of colonization and greater production of the CD enzyme within tumors could be expected with higher TAPET-CD doses. In combination with higher doses of 5-FC, increased colonization of tumor could result in much higher intratumoral 5-FU levels and thus greater antitumor efficacy. Nevertheless, even at the sub-MTD doses administered in this trial, cytotoxic levels of 5-FU were achieved within the colonized tumors.
The current study demonstrated the important proof of concept that bacteria could produce clinically relevant concentrations of functional CD enzyme within tumor. Based on studies conducted with the parent VNP20009, it would appear that VNP20009 and TAPET-CD do not Although ideal development of such bacterial vectors is preferably through intravenous administration, direct tumor injection can be beneficial in various clinical settings. For example, a supra-additive interaction between radiation therapy and msbB À auxotrophic (purI) Salmonella has already been shown in the Cloudman S91 xenograft. 30 Supplementation with target selective production of the radiosensitizer, 5-FU, is expected to further enhance this interaction. 31, 32 Insofar as attenuated Salmonella colonizes tumor extracellular compartments rather than tumor cell cytoplasm, use of this vector may resolve the problem of preferential ''suicide'' transduced-cell cytotoxicity (as compared to bystander cells) decreasing bystander effect and, consequently, antitumor efficacy. 33 In addition, the possibility of a CD/5-FC-induced immune mechanism mediating a systemic cytotoxic effect has been postulated but not fully delineated. 34, 35 It is unknown to what degree each individual activity with respect to the peak concentration of intratumor 5-FU, the prolonged intratumor presence of 5-FU, or the oncolytic activity of the delivery vehicle will play in determining overall antitumor effect.
Alternative biologic approaches utilizing replicating infectious organisms such as tumor-selective viral particles are also being explored as possible delivery vehicles for the cytosine deaminase gene. [36] [37] [38] Others have also shown 5-FC conversion to 5-FU in patients receiving cytosine deaminase gene delivered via nonreplicating adenoviral vectors. 38, 39 These preliminary results support future investigation of TAPET-CD at higher doses via intratumoral injection. However, since local regional therapeutics have limited utility in oncology a secondgeneration Salmonella vector expressing CD is undergoing preclinical development for potential intravenous injection. Salmonella expressing the E. coli CD gene J Nemunaitis et al
